Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma (NASDAQ:HZNP) in a research note published on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other analysts also recently issued research reports about the company. UBS set a $16.00 target price on Horizon Pharma and gave the company a buy rating in a research note on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the company a buy rating in a research note on Monday, August 7th. Jefferies Group reaffirmed a buy rating and set a $16.00 target price on shares of Horizon Pharma in a research note on Thursday, October 5th. Cowen reaffirmed a buy rating on shares of Horizon Pharma in a research note on Thursday, September 28th. Finally, Goldman Sachs Group started coverage on Horizon Pharma in a research note on Thursday, September 28th. They set a buy rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $18.75.
Horizon Pharma (NASDAQ:HZNP) opened at $14.06 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The stock has a market capitalization of $2,348.48, a P/E ratio of 10.38, a P/E/G ratio of 1.21 and a beta of 1.31. Horizon Pharma has a 12-month low of $9.45 and a 12-month high of $20.35.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 EPS. equities analysts forecast that Horizon Pharma will post 0.72 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Advantage Investment Management LLC raised its stake in shares of Horizon Pharma by 164.8% in the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Horizon Pharma by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its stake in shares of Horizon Pharma by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares in the last quarter. Family Management Corp bought a new stake in shares of Horizon Pharma in the 2nd quarter worth $131,000. Finally, Ballentine Partners LLC bought a new stake in shares of Horizon Pharma in the 2nd quarter worth $139,000. 86.59% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Horizon Pharma (HZNP) Given a $17.00 Price Target at Cantor Fitzgerald” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/horizon-pharma-hznp-given-a-17-00-price-target-at-cantor-fitzgerald.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.